Molecular cytogenetic lesions in chronic lymphocytic leukemia


Published: June 12, 2009
Abstract Views: 178
PDF: 800
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

In the 90’s, only approximately 50% of chronic lymphocytic leukemia (CLL) could be shown to carry a chromosome defect, a figure reflecting inadequate cell division. The introduction of FISH allowed for the detection of chromosome aberrations in 80% of the cases and every patient could be included in a specific group according to a hierarchical cytogenetic classification as follows: 17p- > 11q- > +12 > 13q- > normal.1 In most studies, approximately 40% of CLLs were shown to carry isolated 13q-, 10-15% of the patients carried +12 or 11q-, 2-5% 17p- or 6q- or 14q32 translocations. The variable incidence of specific lesions in different phases of the disease reflects their correlation with biologic and clinical features (Table 1). Recently, the introduction of effective mitogenic stimulation by oligonucleotides and interleukin-2 (IL-2)2 showed that approximately 30% of CLL without chromosome defects by interphase FISH carried a chromosome lesion by CBA in regions not covered by the FISH panel of probes. Complex karyotypes could be documented in a substantial fraction of cases in association with unfavorable prognostic factors and inferior clinical outcome.2

Supporting Agencies


Cuneo, A., Cavazzini, F., Ciccone, M., Dabusti, M., Cibien, F., Daghia, G., Sofritti, O., Viglione, G., & Rigolin, G. (2009). Molecular cytogenetic lesions in chronic lymphocytic leukemia. Hematology Meeting Reports (formerly Haematologica Reports), 3(3). https://doi.org/10.4081/hmr.v3i3.577

Downloads

Citations